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Abstract
The use of human samples to assess environmental exposure and uptake of chemicals is more than an analytical exercise
and requires consideration of the utility and interpretation of data as well as due consideration of ethical issues. These
aspects are inextricably linked.
In 2004 the EC expressed its commitment to the development of a harmonised approach to human biomonitoring (HBM)
by including an action in the EU Environment and Health Strategy to develop a Human Biomonitoring Pilot Study. This
further underlined the need for interpretation strategies as well as guidance on ethical issues. A workshop held in
December 2006 brought together stakeholders from academia, policy makers as well as non-governmental organisations
and chemical industry associations to a two day workshop built a mutual understanding of the issues in an open and frank
discussion forum. This paper describes the discussion and recommendations from the workshop.
The workshop developed key recommendations for a Pan-European HBM Study:
1. A strategy for the interpretation of human biomonitoring data should be developed.
2. The pilot study should include the development of a strategy to integrate health data and environmental monitoring
with human biomonitoring data at national and international levels.
3. Communication strategies should be developed when designing the study and evolve as the study continues.
4. Early communication with stakeholders is essential to achieve maximum efficacy of policy developments and facilitate
subsequent monitoring.
5. Member states will have to apply individually for project approval from their National Research Ethics Committees.
6. The study population needs to have sufficient information on the way data will be gathered, interpreted and
disseminated and how samples will be stored and used in the future (if biobanking) before they can give informed consent.
7. The participants must be given the option of anonymity. This has an impact on follow-up.
8. The pilot study should develop guidelines and best practice for Ethics for pan European studies.
In conclusion all participants felt there that there has to be stakeholder involvement in any planned pan-European Human
Biomonitoring Study and the format of the workshop was appropriate for such dialogue.
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Introduction
Biomonitoring is a very useful exposure assessment tool
to assess uptake of chemicals. It has been extensively
applied in the occupational health setting and has in
recent years received increasing attention as a means to
accurately measure low levels of environmental chemicals
in human tissue. The use of human tissue to assess envi-
ronmental exposures is more than an analytical exercise
and requires consideration of the utility and interpreta-
tion of the data as well as due consideration of the ethical
issues. These two aspects are inextricably linked.
In 2003 the European Commission (EC) announced its
Environment and Health Strategy. This strategy contained
many aspects of research and development addressing key
priorities in the developing field of environmental public
health. This led to the European Union (EU) Environ-
ment and Health Action Plan and included an action to
develop a coherent approach to human biomonitoring.
The EC, supported by a multidisciplinary working group
of Member States representatives (Implementation Group
on Human Biomonitoring) and by an Expert team to Sup-
port BIOmonitoring (ESBIO) is preparing an EU Pilot
Project. The Pilot study has been delayed and it is hoped
it will be launched by the end of 2008.
This approach would build on the current capabilities in
many member states (MS) and not only address analytical
and procedural differences between scientific institutes
across Europe that lead to a loss of comparability of
results, but also address legislation and policy differences
between MS. The aims of such a pilot study include the
development of strategies for data interpretation and
communication to the study participants as well as to
numerous other stakeholders. These elements are inextri-
cable from the issues around obtaining approval from
National Research Ethics Committees. These aims are also
further compounded by the needs of a multinational (pan
European) study.
On behalf of the EC (DG ENV), AEA Technology plc and
the UK Health Protection Agency organised a stakeholder
workshop to address issues surrounding data interpreta-
tion and ethical considerations of Human Biomonitoring
(HBM). The organisation was in close cooperation with
European Centre for Ecotoxicology & Toxicology of
Chemicals (ECETOC) and the Health & Environment Alli-
ance (HEAL, formerly EPHA Environment Network) and
the meeting was hosted by the Ministry of the Flemish
Community, Department of Environment, Nature &
Energy in Brussels on the 6th and 7th December 2006.
This workshop brought together stakeholders from across
Europe with expertise and interests in human biomoni-
toring. The participants included academics, policy mak-
ers, and representatives from Non-Governmental
Organization and chemical industry associations. The
purpose of this paper is to summarise the discussion and
recommendations from the workshop and to present
some of the current wider reaching issues. One of the
main aims of the workshop was to produce recommenda-
tions for the pilot project and ESBIO.
Data interpretation issues
The aims of the pilot study should be transparent and real-
istic: it should build capacity across Europe; harmonise
methods and improve efficiency; develop best practice
across Europe; provide data that can be compared cross
boundary; link with other environment and health
research projects; develop policy relevant research recom-
mendations; and ultimately produce a framework for
environment and health research across Europe.
Advances in analytical chemistry have led to the detection
of an ever-increasing number of chemicals with reduced
limits of detection in human samples. This has produced
a dilemma of how to interpret the data and understand
health impacts of the exposures detected and ultimately
how to communicate this information to the public at
individual and societal levels. Recently there has been a
number of reviews, workshops, committees and publica-
tions proposing frameworks for the interpretation of
human biomonitoring data [1-4]. The development of a
standard strategy to interpret human biomonitoring data
would be a huge advance in the field. In order to develop
a standard framework it is important to understand the
type and quality of data required to interpret the results.
The EU emphasizes the development of a coherent
approach to human biomonitoring, to assure appropriate
risk assessment and management for chemicals that influ-
ence human health. Biological monitoring data without
appropriate health based limits can be used to determine
trends or develop reference ranges (background exposure
values). However, it is not possible to determine risk of
adverse health effects or predict such adverse health effects
using human biomonitoring data alone, unless biological
guidance values have been determined for the chemicals
of concern. This has been done for a few chemicals such
as lead and cadmium. The integration of health and expo-
sure data is the ultimate tool in public health. The ulti-
mate goal of a pan European Environment and Human
Health research programme would be to collect human
health, environmental exposure, and biomonitoring data
in a fully integrated system.
Science to policy
Although many HBM studies are carried out across the
EU, few of them have the specific aim to underpin the
development of policy or even to directly involve policyEnvironmental Health 2008, 7(Suppl 1):S13 http://www.ehjournal.net/content/7/S1/S13
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makers in the planning implementation and final com-
munication strategy. In 1977, Council Directive on Bio-
logical Screening of the Population for Lead (77/312/
EEC) committed the EU member states to apply a com-
mon procedure for biological screening in order to assess
the exposure of the population to lead outside the work-
ing environment [5]. Currently the World Health Organi-
sation (WHO) coordinates the fourth in a series of surveys
on determining the level of persistent organic pollutants
(POPs), such as PCBs in human breast milk through out
the world. The aim is to test the efficiency of policy agree-
ments under the Stockholm Convention on POPs. There
are many other examples – for European level policy rele-
vant studies to be carried out it is necessary to consult pol-
icy representatives from all MS. Furthermore, to be able to
monitor the impact of such policy there is a need to har-
monize data gathering and surveillance.
Communication is a dynamic task and requires the devel-
opment of tailored material for many groups of stake-
holders. Early and regular two-way communication with
all stakeholders may provide a means to assess the utility
and ensure the appropriate direction of the program of
work. The use of workshops to discuss key issues is a use-
ful means of not only instigating discussion but also leads
to trust and 'buy in' from the participants.
Specific issues and recommendations
1. A harmonised European human biomonitoring pro-
gramme is necessary and timely.
2. The aims of the pilot study should be transparent and
realistic.
3. A sound strategy for the interpretation of human bio-
monitoring data should be developed.
4. The pilot study should include the development of a
strategy to integrate health data and environmental mon-
itoring data with human biomonitoring data at a national
and international level.
5. Communication strategies should be in place when
designing the study and develop as the study continues.
6. Early communication with key stakeholders is essential
in order to achieve maximum efficacy of any policy devel-
opments and facilitate subsequent monitoring.
Ethical issues
Research should be undertaken in accordance with com-
monly agreed standards of good practice such as are laid
down in the Declaration of Helsinki. These fundamental
and widely accepted ethical principles, largely derived
from medical practice, are:
￿ Beneficence – 'do positive good'
￿ Non-maleficance – 'do no harm'
￿ Informed Consent
￿ Privacy and dignity
There are a number of key phrases that describe the system
of ethical standards that the contemporary social and
medical research establishment has created to try to pro-
tect better the rights of their research participants. The
principle of voluntary participation requires that people
are not coerced into participating in research. However,
the participants should be reimbursed in line with the
inconvenience they incur. The offer of incentives such as
'cinema tickets' or a voucher is practiced in some MS and
may need to be considered for the pan European study.
Closely related to the notion of voluntary participation is
the requirement of informed consent. Essentially, this
means that prospective research participants must be fully
informed about the procedures and risks involved in the
research and must give their consent to participate. Ethical
standards also require that researchers will not put partic-
ipants in a situation where they might be at risk of harm
as a result of their participation. All MS must meet these
standards and any communication plan should include
information on the interpretation of the data produced.
Almost all research guarantees the participant's confiden-
tiality – the participants are assured that identifying infor-
mation will not be made available to anyone who is not
directly involved in the study. For the purposed of a pan
European study the data within country should be coded
before it is collated on European database and national
data protection legislation must be adhered to.
The stricter standard is the principle of anonymity. This
essentially means that the participant will remain anony-
mous throughout the study – even to the researchers
themselves. Clearly, the anonymity standard is a stronger
guarantee of privacy and must be adhered to if a partici-
pant wishes not to know their individual results in any
form. This has implications for a European Environment
and Health Strategy where HBM data and environmental
data are to be integrated. It will be necessary to make sure
the data are geographically identifiable if not linked to
individual participants. This will also impact on the pan-
European HBM study if sequential samples from individ-
uals or interventions are foreseen. This is a major consid-
eration when designing the study.
In 1998 the European Group on Ethics (EGE) stated that
there was an urgent need to regulate human tissues in the
EU market. A series of meetings led to the drafting of theEnvironmental Health 2008, 7(Suppl 1):S13 http://www.ehjournal.net/content/7/S1/S13
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Tissue and Cells Directive (TCD, Directive 2004/23/EC)
[6] that has now been adopted. However, national level
legislation may differ substantially and will need to be
considered. For example, in the UK there is a Human Tis-
sue Act 2004 which stipulates where and how samples can
be stored and requires licences to be applied for; it also
provides guidelines on consent.
As the European biomonitoring study is an exposure and
uptake assessment study and not a clinical trial, the added
complications with the ethical issue of a person's right to
service need be considered in the context of public health
interventions. The need for service normally encompasses
treatment or use of a placebo. In the context of a pro-
gramme of monitoring for involuntary environmental
exposure the need for service considers exposure mitiga-
tion in circumstances where high exposures are detected.
The possibility of repeat sampling and/or interventions to
reduce exposure has further impact on the participants
'right not to know'.
It is clear that there needs to be a procedure that assures
that researchers will consider all relevant ethical issues in
formulating the research design. All Member MSs have
Research Ethics Committees (RECs) and although most of
the legislation has some commonality as discussed above
there are some conflicting issues. It is important that any
research effort on a pan European scale must comply with
National guidelines and protocols and it will be necessary
for each MS to seek ethical approval on an individual
basis.
There is a general recognition that the ethics environment
is changing and international generated guidelines [7]
and standards, such as those developed by the European
Union, are one of several influences on this process of
change. Research is increasingly international in scope in
terms of topic, and data generated. New international
research networks funded by programmes such as those of
the European Union (e.g. the FP6 programme) result in
greater opportunity for collaborative research across bor-
ders [8]. Currently it is necessary for each participating
Member State to obtain ethical approval individually. The
ideal situation would be that international projects be
able to apply for 'international ethical approval'. This
would require EU level Ethic Committees with adequate
representation or knowledge of each member states'
requirements. Subsequent to the initial pan European
pilot study it may be possible to develop European Guide-
lines for Ethics in Human Biomonitoring in particular.
This would be a significant output from the pilot study.
The starting premise of any new framework must be to
review the current practice as is being carried out but the
EU funded projects such as RESPEPT [9], ESBIO, New-
Generis [10], ECNIS [10] and others. In the UK, for exam-
ple, the Economic and Social Research Council (ESRC)
has produced a Research Ethics Framework [11] that has
been developed after informed understanding of global
and other regional or national legal and regulatory frame-
works. This framework clearly sets out the issues and prin-
ciples as were also discussed in the stakeholder workshop.
The framework goes further to develop protocols and
checklists. There are many such developments that require
some streamlining. An output from the pilot study would
be generic guidelines and templates to guide subsequent
EU research projects. This was one of the recommenda-
tions from the workshop.
Specific issues and recommendations
1. Member states will have to apply for project approval
from their National Research Ethics Committees.
2. The study population needs to have sufficient informa-
tion on the way data will be gathered, interpreted and dis-
seminated and how samples will be stored and used in the
future (if biobanking) before they can give informed con-
sent.
3. The participants must be given the option of anonym-
ity. This has an impact on follow-up.
4. The pilot study should develop guidelines and best
practice for future pan European studies. This may lead to
developing an EU level Research Ethics Committee.
Conclusion
The application of human biomonitoring in public health
studies needs the involvement of all stakeholders as part
of the discussion group at the planning stage of a project.
This will allow research to focus on issues related to public
concern and be policy relevant.
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